OBJECTIVE: To assess the antibody response to hepatitis B immunization in HIV-infected and uninfected infants. DESIGN: Cohort, comparing hepatitis B surface-antibody responses of HIV-infected infants with HIV-exposed but uninfected infants. SETTING: Urban children's hospital outpatient clinic for families with HIV-infected members. INTERVENTION: All infants received hepatitis B vaccine according to the American Academy of Pediatrics and Centers for Disease Control and Prevention recommended schedule. RESULTS: Forty-one HIV-exposed or infected infants were immunized with hepatitis B vaccine in the first year of life. Twenty-two out of 24 (92%) HIV-exposed but uninfected infants demonstrated an antibody response to hepatitis B immunization, compared with six out of 17 (35%) HIV-infected infants (P < 0.0005). CD4 percentage and CD4 counts were significantly lower in the HIV-infected infants than in the uninfected infants, but there was no significant difference in CD4 count or percentage between HIV-infected responders and nonresponders. CONCLUSION: The humoral immune response to hepatitis B immunization, administered before 12 months of age, is significantly reduced in HIV-infected children and is independent of CD4 count. Given the large number of infants born each year to pregnant women coinfected with HIV and hepatitis B, further studies to assess the efficacy of increased doses of antigen and variations in the dosage schedule are urgently needed.
OBJECTIVE: To assess the antibody response to hepatitis B immunization in HIV-infected and uninfected infants. DESIGN: Cohort, comparing hepatitis B surface-antibody responses of HIV-infectedinfants with HIV-exposed but uninfected infants. SETTING: Urban children's hospital outpatient clinic for families with HIV-infected members. INTERVENTION: All infants received hepatitis B vaccine according to the American Academy of Pediatrics and Centers for Disease Control and Prevention recommended schedule. RESULTS: Forty-one HIV-exposed or infected infants were immunized with hepatitis B vaccine in the first year of life. Twenty-two out of 24 (92%) HIV-exposed but uninfected infants demonstrated an antibody response to hepatitis B immunization, compared with six out of 17 (35%) HIV-infectedinfants (P < 0.0005). CD4 percentage and CD4 counts were significantly lower in the HIV-infectedinfants than in the uninfected infants, but there was no significant difference in CD4 count or percentage between HIV-infected responders and nonresponders. CONCLUSION: The humoral immune response to hepatitis B immunization, administered before 12 months of age, is significantly reduced in HIV-infectedchildren and is independent of CD4 count. Given the large number of infants born each year to pregnant women coinfected with HIV and hepatitis B, further studies to assess the efficacy of increased doses of antigen and variations in the dosage schedule are urgently needed.
Authors: George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: Patricia M Flynn; Coleen K Cunningham; Bret Rudy; Craig M Wilson; Bill Kapogiannis; Carol Worrell; James Bethel; Dina Monte; Kelly Bojan Journal: J Acquir Immune Defic Syndr Date: 2011-04 Impact factor: 3.731
Authors: Mark J Abzug; Meredith Warshaw; Howard M Rosenblatt; Myron J Levin; Sharon A Nachman; Stephen I Pelton; William Borkowsky; Terence Fenton Journal: J Infect Dis Date: 2009-09-15 Impact factor: 5.226
Authors: Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke Journal: MMWR Recomm Rep Date: 2009-09-04
Authors: Anne Esther Njom Nlend; Philippe Salomon Nguwoh; Christian Taheu Ngounouh; Hyppolite Kuekou Tchidjou; Constant Anatole Pieme; Jean Mbede Otélé; Véronique Penlap; Vittorio Colizzi; Roger Somo Moyou; Joseph Fokam Journal: PLoS One Date: 2016-09-22 Impact factor: 3.240